Acamprosate Fragile X Syndrome (Ages 5-22)
The purpose of this study is to learn more about the effectiveness of acamprosate versus placebo as a drug treatment for interfering symptoms associated with fragile X syndrome, such as irritability, hyperactivity and social impairment. This study will also help determine the amount of medicine that will be used in future treatment for children with FXS. Nationwide, 48 patients will be recruited for this study. At Rush University Medical Center, we expect to recruit approximately 24 patients. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Are between the ages of 5 and 22 with a diagnosis of fragile X syndrome.
- Are able to swallow a large-capsule medication.
You will be excluded from the study if any of the following criteria apply to you:
- Are taking more than two psychotropic drugs.
- Have an unstable seizure disorder or a recent change in anti-convulsant drug dosing.
This is a partial list of eligibility requirements.